Denovobio
1 known investors
De novo Biotherapeutics is a biotherapeutics company developing an mRNA platform to make high-end therapies more affordable. Its lead work focuses on mRNA-based engagers targeting relapsed or refractory cancers, with plans for phase 1 clinical studies.
Also known as De novo Biotherapeutics ยท De Novo Biotherapeutics ยท ๋๋ ธ๋ณด ๋ฐ์ด์คํ ๋ผํจํฑ์ค ยท ์ฃผ์ํ์ฌ ๋๋ ธ๋ณด ๋ฐ์ด์คํ ๋ผํจํฑ์ค
Investors ยท 1
Company profile
researched Aug 2026De novo Biotherapeutics (๋๋ ธ๋ณด ๋ฐ์ด์คํ ๋ผํจํฑ์ค) is a South Korean biotherapeutics company headquartered in Seoul that develops therapies built on an mRNA platform, with the stated aim of making high-end biotherapeutics more affordable. Its primary target indication is relapsed or refractory cancer, and the company designs mRNA engagers directed at new targets, prioritizing three lead candidates.
External pipeline records list five preclinical programs: DNB-101 (non-Hodgkin lymphoma), DNB-102 (multiple myeloma), DNB-103 (acute myeloid leukemia), DNB-104 (acute lymphoblastic leukemia) and DNB-105 (hepatocellular carcinoma). All are recorded at preclinical stage, with mRNA as the drug type and disease areas spanning neoplasms, hemic and lymphatic diseases, and immune system diseases. The company's website has stated an objective of initiating a phase 1 clinical study, and its corporate notices indicate multiple issuances of redeemable convertible preferred shares to third-party investors.
Traction
Five programs (DNB-101 through DNB-105) are recorded at preclinical stage as of pipeline snapshots dated 2026; no clinical-stage assets are listed. The company has issued redeemable convertible preferred shares to third-party investors in 2025 and 2026.
Latest developments
In June 2025 the company published a notice of a third-party allocation issuing 170,010 series-5 redeemable convertible preferred shares at KRW 5,882 per share for total payment of KRW 999,998,820, with payment due 30 June 2025. In March 2026 it announced a further third-party allocation of 118,990 series-6 redeemable convertible preferred shares at KRW 4,202 per share for total payment of KRW 499,995,980, with payment due 16 April 2026. A fifth-term balance sheet settlement announcement was posted on 31 March 2026.
โธFull profile โ market position, technology, go-to-market, geography, history
Market position
The company positions its mRNA platform as a route to lowering the cost of high-end biotherapeutics, and its engager candidates target new targets in relapsed or refractory cancers.
Technology
The company describes an mRNA platform used to design and build mRNA-based engagers against new targets. Pipeline records classify all five of its disclosed programs as mRNA drugs.
Go-to-market
The company's programs address patients with relapsed or refractory cancers, including non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia and hepatocellular carcinoma.
Geography
Headquarters at S-Tower 17F, 82 Saemunan-ro, Jongno-gu, Seoul 03185, Republic of Korea.
History
Corporate records list De Novo Biotherapeutics as founded in 2021 and based in Seoul, South Korea. Notices published by the company track its annual cycle of shareholder meetings and financial statement filings, including third-term (2024), fourth-term (2025) and fifth-term (2026) settlement announcements. The fourth annual general meeting was convened for 19 March 2025 at the company's head office on the 17th floor of S-Tower, 82 Saemunan-ro, Jongno-gu, Seoul, with agenda items covering approval of the 2024 financial statements, director remuneration limits and the reappointment of non-executive directors Kim Dong-myung and Chang Chan-il. Choi Chang-hoon is identified as representative director.
Compiled by commissioned research from 5 cited public sources โ announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed โ not independently audited.
Timeline ยท 3
launches, deals, and filingsNotice of new share issuance by third-party allocation: 118,990 series-6 redeemable convertible preferred shares, par value KRW 100, issue price KRW 4,202 per share, total payment KRW 499,995,980, payment date 16 April 2026.
Notice of new share issuance by third-party allocation: 170,010 series-5 redeemable convertible preferred shares, par value KRW 100, issue price KRW 5,882 per share, total payment KRW 999,998,820, payment date 30 June 2025.
Meeting held at the company's Seoul head office to approve fiscal 2024 financial statements, director remuneration limits, and reappointment of non-executive directors Kim Dong-myung and Chang Chan-il.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
โธResearch sources ยท 5
primary sources listed
- Denovobiodenovobio.co.kr ยท web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Denovobio do?
- Seoul-based biotherapeutics company developing mRNA engager candidates for relapsed or refractory blood cancers and solid tumors.
- Who are Denovobio's investors?
- Denovobio's investors include Atinum Investment Co. Ltd..